Johnson & Johnson Research and Development Expenses 2010-2024 | JNJ

Johnson & Johnson annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Johnson & Johnson research and development expenses for the quarter ending September 30, 2024 were $4.952B, a 43.66% increase year-over-year.
  • Johnson & Johnson research and development expenses for the twelve months ending September 30, 2024 were $16.414B, a 16.49% increase year-over-year.
  • Johnson & Johnson annual research and development expenses for 2023 were $15.085B, a 6.72% increase from 2022.
  • Johnson & Johnson annual research and development expenses for 2022 were $14.135B, a 0.99% decline from 2021.
  • Johnson & Johnson annual research and development expenses for 2021 were $14.277B, a 17.42% increase from 2020.
Johnson & Johnson Annual Research and Development Expenses
(Millions of US $)
2023 $15,085
2022 $14,135
2021 $14,277
2020 $12,159
2019 $11,355
2018 $10,775
2017 $10,594
2016 $9,143
2015 $9,046
2014 $8,494
2013 $8,183
2012 $7,665
2011 $7,548
2010 $6,844
2009 $6,986
Johnson & Johnson Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $4,952
2024-06-30 $3,440
2024-03-31 $3,542
2023-12-31 $4,480
2023-09-30 $3,447
2023-06-30 $3,703
2023-03-31 $3,455
2022-12-31 $3,485
2022-09-30 $3,485
2022-06-30 $3,703
2022-03-31 $3,462
2021-12-31 $4,283
2021-09-30 $3,422
2021-06-30 $3,394
2021-03-31 $3,178
2020-12-31 $4,032
2020-09-30 $2,840
2020-06-30 $2,707
2020-03-31 $2,580
2019-12-31 $3,232
2019-09-30 $2,599
2019-06-30 $2,666
2019-03-31 $2,858
2018-12-31 $3,224
2018-09-30 $2,508
2018-06-30 $2,639
2018-03-31 $2,404
2017-12-31 $3,643
2017-09-30 $2,585
2017-06-30 $2,296
2017-03-31 $2,070
2016-12-31 $2,688
2016-09-30 $2,178
2016-06-30 $2,264
2016-03-31 $2,013
2015-12-31 $2,864
2015-09-30 $2,154
2015-06-30 $2,129
2015-03-31 $1,899
2014-12-31 $2,635
2014-09-30 $2,023
2014-06-30 $2,005
2014-03-31 $1,831
2013-12-31 $2,411
2013-09-30 $2,042
2013-06-30 $1,946
2013-03-31 $1,784
2012-12-31 $2,331
2012-09-30 $1,923
2012-06-30 $1,766
2012-03-31 $1,645
2011-12-31 $2,155
2011-09-30 $1,773
2011-06-30 $1,882
2011-03-31 $1,738
2010-12-31 $1,982
2010-09-30 $1,657
2010-06-30 $1,648
2010-03-31 $1,557
2009-12-31 $2,213
2009-09-30 $1,617
2009-06-30 $1,638
2009-03-31 $1,518
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.366B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94